Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Core Insights - The FDA has accepted the supplemental NDA filing for olezarsen to treat severe hypertriglyceridemia (sHTG) with priority review status, which is a significant development for the company [2][3] - The PDUFA date for olezarsen is set for June 30, indicating a potential launch at the end of June or early July [3] Company Positioning - The company is well-positioned for continued success, having experienced a pivotal and transformational year in 2025 [3]